AstraZeneca announces $15 billion investment in China through 2030 for cell therapy, radioconjugates, and manufacturing expansion, unveiled during Keir Starmer’s visit. Aligns with Healthy China 2030, strengthening UK ties and global drug pipeline.
Written By: Pharmacally Medical News Desk
AstraZeneca announced a landmark $15 billion investment in China through 2030 to expand manufacturing, R&D, and cross-border healthcare innovation. The move leverages China’s scientific expertise, advanced manufacturing, and growing UK-China collaborations to speed up cutting-edge treatments for patients worldwide.
The reveal came during UK Prime Minister Keir Starmer’s official visit to China, underscoring AstraZeneca’s regional strategy and life sciences ties between the nations.
UK Government Stresses Global and Domestic Wins
Prime Minister Starmer highlighted how the expansion fuels international growth while boosting the UK economy.
“Unlocking opportunities for British businesses across the globe and delivering for working people back home is always the driving force behind my international engagements,” Starmer said. He noted it will sustain thousands of UK jobs and strengthen the life sciences sector via research partnerships.
CEO Outlines Next-Gen Focus
AstraZeneca CEO Pascal Soriot called the investment a “new chapter” for the company’s China strategy, praising the country’s role in global innovation.
“Today’s landmark investment of $15 billion begins an exciting next chapter for AstraZeneca in China,” Soriot said. It targets breakthroughs in cell therapy and radioconjugates to advance oncology, haematology, autoimmune diseases, and other serious conditions.
Full-Chain Cell Therapy Buildout
AstraZeneca will enhance end-to-end capabilities from discovery and trials to large-scale manufacturing in cell therapy and radioconjugates. Key partnerships include Chinese biotechs like AbelZeta, CSPC, Harbour BioMed, Jacobio, and Syneron Bio. Building on its 2024 Gracell Biotechnologies acquisition, AstraZeneca aims to lead as the first global pharma with full cell therapy operations in China.
R&D and Manufacturing Growth
The company’s Beijing and Shanghai R&D centres already collaborate with over 500 clinical hospitals and lead global trials. Manufacturing in Wuxi, Taizhou, Qingdao, and Beijing supplies 70+ markets; new sites are planned.
This will grow AstraZeneca’s China workforce past 20,000, creating thousands more ecosystem jobs.
Deepening China-UK Innovation Links
The investment bolsters ties with UK partners like University of Cambridge (existing), University of Oxford, University of Glasgow, King’s College London, and HSBC linking research, finance, and innovation.
Fit with Healthy China 2030
Efforts align with China’s Healthy China 2030 and “Common Health” goals, emphasizing prevention, early detection, and access to innovative therapies for underserved groups.
References
AstraZeneca plans to invest $15 billion in China through 2030 to pioneer the next-generation of innovative medicines, 29 January 2026, AstraZeneca plans to invest $15 billion in China through 2030 to pioneer the next-generation of innovative medicines